BACKGROUND: Bleeding complications are common and decrease the odds of survival in @entity1 supported with extracorporeal membrane oxygenation (ECMO). The role of @entity1423 on ECMO-induced @entity1003 and resultant @entity548 complications is not well understood. The primary objective of this pilot study was to determine the incidence and magnitude of @entity1423 according to thromboelastography ( @entity17792 (  ))-platelet mapping (PM) testing. METHODS: Retrospective chart review of @entity1 <18   years old who required ECMO at a tertiary level hospital. We collected @entity17792 (  )-PM and conventional coagulation tests data. We also collected demographic, medications, blood products administered, and clinical outcome data. We defined severe @entity1423 as <50% aggregation in response to an agonist. RESULTS: We identified 24 out of 46 @entity1 on ECMO, who had @entity17792 (  )-PM performed during the study period. We found the incidence of severe @entity548 was 42% and mortality was 54% in our study cohort. In all samples measured, severe qualitative @entity1423 was more common for @entity857 ( @entity857 )-mediated aggregation (92%) compared to @entity1426 (AA)-mediated aggregation (75%) (p   =   0.001). Also, @entity857 -mediated percent of @entity1423 was significant lower than AA-mediated @entity1423 [15% (interquartile range, IQR 2.8-48) vs. 49% (IQR 22-82.5), p   <   0.001]. There was no difference in @entity4563 -activated heparinase @entity17792 (  ) parameters between the @entity548 group and the non- @entity548 group. Only absolute platelet count and @entity17792 (  )-PM had increased predictive value on receiver operating characteristics analyses for severe @entity548 and mortality compared to activated clotting time. CONCLUSION: We found frequent and severe qualitative @entity1423 on @entity17792 (  )-PM testing in @entity1 on ECMO. Larger studies are needed to determine if the assessment of qualitative platelet function by @entity17792 (  )-PM can improve prediction of @entity548 complications for @entity1 on ECMO.

Incidence of XXXX by Thromboelastography-Platelet Mapping in @entity1 Supported with ECMO: A Pilot Retrospective Study.

@entity1 :: ('9606', 'Species') :: ['children'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation', 'platelet dysfunction'] @entity4563 :: ('MESH:D007616', 'Chemical') :: ['kaolin'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathy'] @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid'] @entity17792 :: ('CHEBI:44926', 'Chemical') :: ['TEG'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['ADP', 'adenosine diphosphate']
@entity1423 :: (MESH:D001791,Disease) :: ['Platelet Dysfunction']
